| 前收市價 | 167.80 |
| 開市 | 167.66 |
| 買盤 | 168.97 x 800 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 165.57 - 169.29 |
| 52 週波幅 | 130.96 - 182.89 |
| 成交量 | |
| 平均成交量 | 5,630,903 |
| 市值 | 296.212B |
| Beta 值 (5 年，每月) | 0.56 |
| 市盈率 (最近 12 個月) | 61.28 |
| 每股盈利 (最近 12 個月) | 2.73 |
| 業績公佈日 | 2024年4月26日 |
| 遠期股息及收益率 | 6.20 (3.71%) |
| 除息日 | 2024年4月12日 |
| 1 年預測目標價 | 184.70 |
ReutersCigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
ZacksZacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
